Our investment in Delfa to fix clinical trials
Clinical trials are the bottleneck of the pharmaceutical industry. They’re slow, expensive, and often fail, not only because the science frequently doesn’t pan out, but because the ops don’t either. That’s why we’re leading the $3.8M Seed round for Delfa. The team is building an AI-native operating system for clinical trials, starting with patient enrolment, the most broken part of the process.